359 related articles for article (PubMed ID: 34946546)
1. Emerging Therapeutic Agents for Colorectal Cancer.
Nalli M; Puxeddu M; La Regina G; Gianni S; Silvestri R
Molecules; 2021 Dec; 26(24):. PubMed ID: 34946546
[TBL] [Abstract][Full Text] [Related]
2. Tropomyosin-related kinase B/brain derived-neurotrophic factor signaling pathway as a potential therapeutic target for colorectal cancer.
Akil H; Perraud A; Jauberteau MO; Mathonnet M
World J Gastroenterol; 2016 Jan; 22(2):490-500. PubMed ID: 26811602
[TBL] [Abstract][Full Text] [Related]
3. Precision medicine for metastatic colorectal cancer: an evolving era.
Guler I; Askan G; Klostergaard J; Sahin IH
Expert Rev Gastroenterol Hepatol; 2019 Oct; 13(10):919-931. PubMed ID: 31475851
[No Abstract] [Full Text] [Related]
4. Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies.
Tie J; Desai J
Target Oncol; 2015 Jun; 10(2):179-88. PubMed ID: 25119972
[TBL] [Abstract][Full Text] [Related]
5. Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers.
Temraz S; Mukherji D; Shamseddine A
Int J Mol Sci; 2015 Sep; 16(9):22976-88. PubMed ID: 26404261
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: Focusing on Regorafenib.
Papadimitriou M; Papadimitriou CA
Anticancer Res; 2021 Feb; 41(2):567-582. PubMed ID: 33517262
[TBL] [Abstract][Full Text] [Related]
7. Targeting PI3K signaling as a therapeutic approach for colorectal cancer.
Zhang J; Roberts TM; Shivdasani RA
Gastroenterology; 2011 Jul; 141(1):50-61. PubMed ID: 21723986
[TBL] [Abstract][Full Text] [Related]
8. Treatment options in BRAF-mutant metastatic colorectal cancer.
Bernabe-Ramirez C; Patel R; Chahal J; Saif MW
Anticancer Drugs; 2020 Jul; 31(6):545-557. PubMed ID: 32304411
[TBL] [Abstract][Full Text] [Related]
9. HER2: An emerging target in colorectal cancer.
Greally M; Kelly CM; Cercek A
Curr Probl Cancer; 2018 Nov; 42(6):560-571. PubMed ID: 30100092
[TBL] [Abstract][Full Text] [Related]
10. Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer.
Zhang P; Kawakami H; Liu W; Zeng X; Strebhardt K; Tao K; Huang S; Sinicrope FA
Mol Cancer Res; 2018 Mar; 16(3):378-389. PubMed ID: 29233910
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer.
Pek M; Yatim SMJM; Chen Y; Li J; Gong M; Jiang X; Zhang F; Zheng J; Wu X; Yu Q
Oncogene; 2017 Aug; 36(35):4975-4986. PubMed ID: 28459468
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor: pathway, therapies, and pipeline.
Goffin JR; Zbuk K
Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer.
Hochster HS; Uboha N; Messersmith W; Gold PJ; ONeil BH; Cohen D; Denlinger C; Cohen S; Leichman CG; Leichman L; Lenz HJ
Cancer Chemother Pharmacol; 2015 Jan; 75(1):17-23. PubMed ID: 25322874
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological targeting PTK6 inhibits the JAK2/STAT3 sustained stemness and reverses chemoresistance of colorectal cancer.
Liu C; Pan Z; Chen Q; Chen Z; Liu W; Wu L; Jiang M; Lin W; Zhang Y; Lin W; Zhou R; Zhao L
J Exp Clin Cancer Res; 2021 Sep; 40(1):297. PubMed ID: 34551797
[TBL] [Abstract][Full Text] [Related]
15. Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer.
Matos I; Elez E; Capdevila J; Tabernero J
Expert Opin Emerg Drugs; 2016 Sep; 21(3):267-82. PubMed ID: 27578253
[TBL] [Abstract][Full Text] [Related]
16. Targeting key transcriptional factor STAT3 in colorectal cancer.
Chalikonda G; Lee H; Sheik A; Huh YS
Mol Cell Biochem; 2021 Sep; 476(9):3219-3228. PubMed ID: 33866491
[TBL] [Abstract][Full Text] [Related]
17. Advances in the therapy of BRAF
Jin Z; Sinicrope FA
Expert Rev Anticancer Ther; 2019 Sep; 19(9):823-829. PubMed ID: 31455117
[No Abstract] [Full Text] [Related]
18. Evolving Strategies for the Management of BRAF-Mutant Metastatic Colorectal Cancer.
Lee HM; Morris V; Napolitano S; Kopetz S
Oncology (Williston Park); 2019 Jun; 33(6):206-11. PubMed ID: 31219603
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological cyclin dependent kinase inhibitors: Implications for colorectal cancer.
Balakrishnan A; Vyas A; Deshpande K; Vyas D
World J Gastroenterol; 2016 Feb; 22(7):2159-64. PubMed ID: 26900281
[TBL] [Abstract][Full Text] [Related]
20. Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview.
Lin PS; Semrad TJ
Methods Mol Biol; 2018; 1765():281-297. PubMed ID: 29589315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]